GSM9128162: DFCI282_Ositreated; Homo sapiens; RNA-Seq
We interrogated the availability of surgical specimens of patients who had received neo-adjuvant EGFR-TKIs at Dana-Farber Cancer Institute (Boston, MA, US), at Policlinico Universitario A. Gemelli IRCCS (Rome, Italy) and at Cochin Hospital AP-HP (Paris, France). All patients had signed an informed consent to participate to molecular studies and the studies were approved by the local institutional review boards.